Medicinal Chemistry

	Symposium Organizer Scott Cowen AstraZeneca Contact

Medicinal chemistry is a highly interdisciplinary science combining organic chemistry with biochemistry, computational chemistry, pharmacology, pharmacognosy, molecular biology, statistics, and physical chemistry.

Working at the intersection of chemistry and pharmacology, medicinal chemists identify, synthesize and develop new chemical entities suitable for therapeutic use. The discipline also includes the study of existing drugs, their biological properties, and their quantitative structure-activity relationships (QSAR).

Focus areas

• Lead Generation: Case studies in hit-to-lead chemistry, analysis of triage of HTS results, Library generation for hit expansion, etc.,
• Lead Optimization – Sponsored by AstraZeneca: Case studies across a variety of theraputic areas, illustrating the successful identification and optimization of leads to generate clinical candidates.
• Bench to Pilot plant: Talks highlighting successful preclinical projects resulting in the generation of clinical candidates. Scale-up/Process chemistry – Translational Science – Pre-Clinical challenges, etc.
• Special Topics:Talks showcasing enabling technology in support of drug discovery: Toxicology, Invivo-imaging, Computational methods for DMPK predictions, Stucture-based design, Pro-Drug application, Microwave synthesis, Parallel purification etc.

Papers from industrial authors and authors from Canada are particularly welcome.

General information about NERM2008 abstract submission can be found here.

Submit an abstract for this symposium using the ACS OASYS on-line abstract submission system

All abstracts accepted for NERM 2008 will be automatically included into CAS, the ACS Chemical Abstracts Service database after the meeting.

Invited Speakers

	Terrence Hammil Merck, USA PET Radiochemistry. Synthesis Using Short-Lived Istopes		Adrian Hobson Abbott Bioresearch Center, USA
	Mike Luzzio Novartis FAK inhibitors in Cancer		Mark Ashwell Arqule The Discovery and Early Development of ARQ 197, a Selective c-Met Inhibitor
	Enrico Purisima National Research Council Canada (NRC)		Andreas Goutopoulos EMD Serono, Inc. Lead optimization and candidate selection of novel allosteric MEK inhibitors for the treatment of cancer
	John Macor Bristol-Myers Squibb, USA		David Bauer Amgen The Path to a Potent, Selective and Orally Bioavailable c-Met Inhibitor with Antitumor Activity
	Mark Murko Vertex Pharmaceuticals		Brian Gregg Albany Molecular Research Inc
	Mark Ashwell ArQule		Steven Hannessian Université de Montréal
	Stefan Peukart Novartis Tetramic acids and more: Discovery of potent and selective leads inhibiting undecaprenyl pyrophosphate synthase (UPPS)